WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ: ACUS) today reported financial results for the quarter ended June 30, 2007 and commented on its operational priorities and progress, including its planned NDA submission in Q4 2007 for its lead product candidate, Imagify(TM) (perflubutane polymer microspheres) Injectable Suspension, a cardiovascular drug in late-stage development for use in screening for coronary artery disease.
